Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy.
Leclercq G, Haegel H, Toso A, Zimmermann T, Green L, Steinhoff N, Sam J, Pulko V, Schneider A, Giusti AM, Challier J, Freimoser-Grundschober A, Larivière L, Odermatt A, Stern M, Umana P, Bacac M, Klein C. Leclercq G, et al. Among authors: freimoser grundschober a. J Immunother Cancer. 2022 Jan;10(1):e003766. doi: 10.1136/jitc-2021-003766. J Immunother Cancer. 2022. PMID: 35064010 Free PMC article.
A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma.
Iurlaro R, Waldhauer I, Planas-Rigol E, Bonfill-Teixidor E, Arias A, Nicolini V, Freimoser-Grundschober A, Cuartas I, Martínez-Moreno A, Martínez-Ricarte F, Cordero E, Cicuendez M, Casalino S, Guardia-Reyes X, Fahrni L, Pöschinger T, Steinhart V, Richard M, Briner S, Mueller J, Osl F, Sam J, Colombetti S, Bacac M, Klein C, Pineda E, Reyes-Figueroa L, Di Somma A, González J, Nuciforo P, Carles J, Vieito M, Tabernero J, Umaña P, Seoane J. Iurlaro R, et al. Among authors: freimoser grundschober a. Mol Cancer Ther. 2022 Oct 7;21(10):1499-1509. doi: 10.1158/1535-7163.MCT-22-0201. Mol Cancer Ther. 2022. PMID: 35915983
In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing.
Lehmann S, Perera R, Grimm HP, Sam J, Colombetti S, Fauti T, Fahrni L, Schaller T, Freimoser-Grundschober A, Zielonka J, Stoma S, Rudin M, Klein C, Umana P, Gerdes C, Bacac M. Lehmann S, et al. Clin Cancer Res. 2016 Sep 1;22(17):4417-27. doi: 10.1158/1078-0432.CCR-15-2622. Epub 2016 Apr 26. Clin Cancer Res. 2016. PMID: 27117182
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.
Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, Bianchi R, Richard M, Schoenle A, Nicolini V, Diggelmann S, Limani F, Schlenker R, Hüsser T, Richter W, Bray-French K, Hinton H, Giusti AM, Freimoser-Grundschober A, Lariviere L, Neumann C, Klein C, Umaña P. Bacac M, et al. Clin Cancer Res. 2018 Oct 1;24(19):4785-4797. doi: 10.1158/1078-0432.CCR-18-0455. Epub 2018 May 1. Clin Cancer Res. 2018. PMID: 29716920
p95HER2-T cell bispecific antibody for breast cancer treatment.
Rius Ruiz I, Vicario R, Morancho B, Morales CB, Arenas EJ, Herter S, Freimoser-Grundschober A, Somandin J, Sam J, Ast O, Barriocanal ÁM, Luque A, Escorihuela M, Varela I, Cuartas I, Nuciforo P, Fasani R, Peg V, Rubio I, Cortés J, Serra V, Escriva-de-Romani S, Sperinde J, Chenna A, Huang W, Winslow J, Albanell J, Seoane J, Scaltriti M, Baselga J, Tabernero J, Umana P, Bacac M, Saura C, Klein C, Arribas J. Rius Ruiz I, et al. Sci Transl Med. 2018 Oct 3;10(461):eaat1445. doi: 10.1126/scitranslmed.aat1445. Sci Transl Med. 2018. PMID: 30282693 Free PMC article.
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.
Claus C, Ferrara C, Xu W, Sam J, Lang S, Uhlenbrock F, Albrecht R, Herter S, Schlenker R, Hüsser T, Diggelmann S, Challier J, Mössner E, Hosse RJ, Hofer T, Brünker P, Joseph C, Benz J, Ringler P, Stahlberg H, Lauer M, Perro M, Chen S, Küttel C, Bhavani Mohan PL, Nicolini V, Birk MC, Ongaro A, Prince C, Gianotti R, Dugan G, Whitlow CT, Solingapuram Sai KK, Caudell DL, Burgos-Rodriguez AG, Cline JM, Hettich M, Ceppi M, Giusti AM, Crameri F, Driessen W, Morcos PN, Freimoser-Grundschober A, Levitsky V, Amann M, Grau-Richards S, von Hirschheydt T, Tournaviti S, Mølhøj M, Fauti T, Heinzelmann-Schwarz V, Teichgräber V, Colombetti S, Bacac M, Zippelius A, Klein C, Umaña P. Claus C, et al. Sci Transl Med. 2019 Jun 12;11(496):eaav5989. doi: 10.1126/scitranslmed.aav5989. Sci Transl Med. 2019. PMID: 31189721 Free PMC article.
Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody.
Geiger M, Stubenrauch KG, Sam J, Richter WF, Jordan G, Eckmann J, Hage C, Nicolini V, Freimoser-Grundschober A, Ritter M, Lauer ME, Stahlberg H, Ringler P, Patel J, Sullivan E, Grau-Richards S, Endres S, Kobold S, Umaña P, Brünker P, Klein C. Geiger M, et al. Among authors: freimoser grundschober a. Nat Commun. 2020 Jun 24;11(1):3196. doi: 10.1038/s41467-020-16838-w. Nat Commun. 2020. PMID: 32581215 Free PMC article.
Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Stock S, Benmebarek MR, Kluever AK, Darowski D, Jost C, Stubenrauch KG, Benz J, Freimoser-Grundschober A, Moessner E, Umana P, Subklewe M, Endres S, Klein C, Kobold S. Stock S, et al. Among authors: freimoser grundschober a. J Immunother Cancer. 2022 Jul;10(7):e005054. doi: 10.1136/jitc-2022-005054. J Immunother Cancer. 2022. PMID: 35902133 Free PMC article.
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy.
Waldhauer I, Gonzalez-Nicolini V, Freimoser-Grundschober A, Nayak TK, Fahrni L, Hosse RJ, Gerrits D, Geven EJW, Sam J, Lang S, Bommer E, Steinhart V, Husar E, Colombetti S, Van Puijenbroek E, Neubauer M, Cline JM, Garg PK, Dugan G, Cavallo F, Acuna G, Charo J, Teichgräber V, Evers S, Boerman OC, Bacac M, Moessner E, Umaña P, Klein C. Waldhauer I, et al. Among authors: freimoser grundschober a. MAbs. 2021 Jan-Dec;13(1):1913791. doi: 10.1080/19420862.2021.1913791. MAbs. 2021. PMID: 33974508 Free PMC article.
Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies.
Kerns SJ, Belgur C, Petropolis D, Kanellias M, Barrile R, Sam J, Weinzierl T, Fauti T, Freimoser-Grundschober A, Eckmann J, Hage C, Geiger M, Ng PR, Tien-Street W, Manatakis DV, Micallef V, Gerard R, Bscheider M, Breous-Nystrom E, Schneider A, Giusti AM, Bertinetti-Lapatki C, Grant HS, Roth AB, Hamilton GA, Singer T, Karalis K, Moisan A, Bruenker P, Klein C, Bacac M, Gjorevski N, Cabon L. Kerns SJ, et al. Among authors: freimoser grundschober a. Elife. 2021 Aug 11;10:e67106. doi: 10.7554/eLife.67106. Elife. 2021. PMID: 34378534 Free PMC article.
21 results